Indaptus Therapeutics, Inc.(INDP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

INDP Indaptus Therapeutics, Inc.

Market Closed 07-24 16:00:00 EDT

2.61

-0.16

-5.78%

盘后2.60

-0.01-0.38%

19:49 EDT

High2.88	Low2.57	Vol55.68K
Open2.88	D1 Closing2.77	Amplitude11.37%
Mkt Cap347.13M	Tradable Cap60.66M	Total Shares133.00M
T/O153.16K	T/O Rate0.24%	Tradable Shares23.24M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"INDP","market":"US","secType":"STK","nameCN":"Indaptus Therapeutics, Inc.","latestPrice":2.61,"timestamp":1784923200000,"preClose":2.77,"halted":0,"volume":55678,"hourTrading":{"tag":"盘后","latestPrice":2.6,"preClose":2.61,"latestTime":"19:49 EDT","volume":522,"amount":1357.3419,"timestamp":1784936985946,"change":-0.01,"changeRate":-0.003831,"amplitude":0.003831},"delay":0,"changeRate":-0.05776173285198561,"floatShares":23243100,"shares":133000000,"eps":-16.8254,"marketStatus":"Market Closed","change":-0.16,"latestTime":"07-24 16:00:00 EDT","open":2.88,"high":2.88,"low":2.565,"amount":153155.8798896,"amplitude":0.113718,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-16.8254,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1785139200000},"marketStatusCode":7,"adr":0,"listingDate":1438660800000,"exchange":"NASDAQ","adjPreClose":2.77,"preHourTrading":{"tag":"盘前","latestPrice":2.88,"preClose":2.77,"latestTime":"09:28 EDT","volume":278,"amount":765.1600276,"timestamp":1784899717056,"change":0.11,"changeRate":0.039711,"amplitude":0.101083},"postHourTrading":{"tag":"盘后","latestPrice":2.6,"preClose":2.61,"latestTime":"19:49 EDT","volume":522,"amount":1357.3419,"timestamp":1784936985946,"change":-0.01,"changeRate":-0.003831,"amplitude":0.003831},"volumeRatio":2.20093765272617},"requestUrl":"/m/hq/s/INDP/tweets","defaultTab":"tweets","newsList":[{"id":"2649999894","title":"Insider Traders Lose US$34k As Indaptus Therapeutics Drops","url":"https://stock-news.laohu8.com/highlight/detail?id=2649999894","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649999894?lang=en_us&edition=fundamental","pubTime":"2026-07-08 19:47","pubTimestamp":1783511263,"startTime":"0","endTime":"0","summary":"The recent price decline of 11% in Indaptus Therapeutics, Inc.'s ( NASDAQ:INDP ) stock may have disappointed insiders...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-indp/indaptus-therapeutics/news/insider-traders-lose-us34k-as-indaptus-therapeutics-drops","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-indp/indaptus-therapeutics/news/insider-traders-lose-us34k-as-indaptus-therapeutics-drops","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4539","BK4139","BK4007","LENZ","INDP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646398016","title":"Indaptus Therapeutics Inc - Files for Resale by the Selling Stockholders of up to 18.86 Mln Shares of Common Stock - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2646398016","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646398016?lang=en_us&edition=fundamental","pubTime":"2026-06-27 05:23","pubTimestamp":1782508985,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260626:nFWN42Y11C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["INDP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646843066","title":"Indaptus Therapeutics - to Issue 20 Mln Shares at $0.6 Per Share - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2646843066","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646843066?lang=en_us&edition=fundamental","pubTime":"2026-06-25 04:02","pubTimestamp":1782331379,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nFWN42W07S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","INDP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646025843","title":"Indaptus Therapeutics - Private Placement Gross Proceeds About $12 Mln Before Expenses - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2646025843","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646025843?lang=en_us&edition=fundamental","pubTime":"2026-06-25 04:02","pubTimestamp":1782331379,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nFWN42W07S:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","INDP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646843067","title":"Indaptus Therapeutics Sells 20,000,000 Shares at $0.6 in $12 Million Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2646843067","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646843067?lang=en_us&edition=fundamental","pubTime":"2026-06-25 04:02","pubTimestamp":1782331345,"startTime":"0","endTime":"0","summary":"Indaptus Therapeutics sells 20,000,000 shares at $0.6 in $12 million private placementIndaptus Therapeutics priced a private placement of 20,000,000 common shares at USD 0.6 each.Gross proceeds totale","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nNDL2j8K2B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INDP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641792117","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2641792117","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641792117?lang=en_us&edition=fundamental","pubTime":"2026-06-05 19:43","pubTimestamp":1780659837,"startTime":"0","endTime":"0","summary":"Indaptus Therapeutics  shares were down 35% in Friday premarket activity, following the previous session's 115% gain.Cypherpunk Technologies  stock was down 34% after the company confirmed a bug in the Zcash cryptocurrency network.Nuwellis  shares were down 30% after the company filed a preliminary prospectus with the US Securities and Exchange Commission for a best-efforts offering of up to 6.6 million shares, or pre-funded warrants.Splash Beverage Group  stock was down 29% following Thursday's 38% gain.Lianhe Sowell  shares were down 27%, extending the previous session's 2.8% decline.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["INDP","BK4169","BK4140","NUWE","BK4113","BK4139","CYPH","LHSW","SBEV","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641169985","title":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 12:47 PM","url":"https://stock-news.laohu8.com/highlight/detail?id=2641169985","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641169985?lang=en_us&edition=fundamental","pubTime":"2026-06-05 00:47","pubTimestamp":1780591632,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 12:47 PM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nAQN2M26UU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INDP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635927086","title":"Indaptus Therapeutics Q1 net loss narrows as expenses fall","url":"https://stock-news.laohu8.com/highlight/detail?id=2635927086","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635927086?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:07","pubTimestamp":1778843263,"startTime":"0","endTime":"0","summary":"Indaptus Therapeutics Q1 net loss narrows as expenses fallOverviewU.S. biotech firm's Q1 net loss narrowed as operating expenses declinedCompany is reassessing development priorities after executive m","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nL1N41S0FH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INDP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635809086","title":"Indaptus net loss narrows to $2.5 million in Q1 FY26; R&D expenses drop 82% to $491,134","url":"https://stock-news.laohu8.com/highlight/detail?id=2635809086","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635809086?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:01","pubTimestamp":1778842902,"startTime":"0","endTime":"0","summary":"Indaptus Therapeutics posted a first-quarter net loss of USD 2.54 million, narrowing from USD 4.53 million a year earlier; loss per share improved to USD 0.23 from USD 9.11.Research and development expense fell to 491,134 from USD 2.81 million a year earlier, due to lower Phase 1 clinical costs and reduced payroll tied to headcount and salary cuts.Cash and cash equivalents dropped to USD 1.5 million at March 31 from USD 8.51 million at Dec. 31; net cash used in operating activities increased to USD 7.01 million from USD 5.05 million.Management said it is reassessing development priorities and evaluating the Decoy platform’s preclinical data and scientific rationale, while reviewing operating initiatives, resource allocation, financing alternatives, and strategic options.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDL5bqhJg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","SG9999014021.USD","IE00B64PRP62.GBP","SG9999014005.SGD","INDP","LU0314104364.USD","IE00B3QW5Z07.USD","LU2095319765.USD","IE00BN0W2V16.EUR","LU2210149790.SGD","SG9999014039.USD","BK4112","BK4585","IE00BGHQF748.EUR","SG9999014013.SGD","BK4139","NDAQ","IE00BN0W2W23.USD","LU2210150020.SGD","IE00BN0W2T93.GBP","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635076085","title":"Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635076085","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635076085?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:00","pubTimestamp":1778842802,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nTUA3RTD0B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["INDP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635850460","title":"Indaptus Therapeutics Q1 EPS USD -0.23","url":"https://stock-news.laohu8.com/highlight/detail?id=2635850460","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635850460?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:00","pubTimestamp":1778842802,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nPLX467CC4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","INDP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633746837","title":"Indaptus Therapeutics Inc  expected to post a loss of $1.87 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2633746837","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633746837?lang=en_us&edition=fundamental","pubTime":"2026-05-08 23:30","pubTimestamp":1778254212,"startTime":"0","endTime":"0","summary":"Indaptus Therapeutics Inc  expected to post a loss of $1.87 a share - Earnings Preview Indaptus Therapeutics Inc INDP.OQ INDP.O is expected to  report resultson May 12 (estimated) for the period endin","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nL8N41L1UU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INDP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630820339","title":"Indaptus amends 8-K to reflect director Johnny Fox Arrowsmith legal name change","url":"https://stock-news.laohu8.com/highlight/detail?id=2630820339","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630820339?lang=en_us&edition=fundamental","pubTime":"2026-04-25 05:01","pubTimestamp":1777064489,"startTime":"0","endTime":"0","summary":"Indaptus Therapeutics filed an amended Form 8-K to correct a director name disclosed in an April 23, 2026 report.Director previously identified as Yi Zhang  changed legal name to Johnny Fox Arrowsmith.Arrowsmith uses “Yi Zhang” as his professional name.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Indaptus Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 24, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260424:nNDL6CtCMx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INDP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629775128","title":"Indaptus Therapeutics director Qinglai Lu files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2629775128","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629775128?lang=en_us&edition=fundamental","pubTime":"2026-04-21 04:06","pubTimestamp":1776715616,"startTime":"0","endTime":"0","summary":"Indaptus Therapeutics filed an initial beneficial ownership statement naming Qinglai Lu as a director, dated April 8, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Indaptus Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 20, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nNDL8wdD8r:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INDP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624654276","title":"Indaptus Therapeutics Inc - Appoints Yu Ding as CFO Effective April 1, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2624654276","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624654276?lang=en_us&edition=fundamental","pubTime":"2026-04-04 00:01","pubTimestamp":1775232081,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260403:nFWN40L141:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","INDP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624665428","title":"Indaptus Therapeutics names Yu Ding CFO after Nir Sassi resignation","url":"https://stock-news.laohu8.com/highlight/detail?id=2624665428","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624665428?lang=en_us&edition=fundamental","pubTime":"2026-04-04 00:00","pubTimestamp":1775232056,"startTime":"0","endTime":"0","summary":"Indaptus Therapeutics named Yu Ding chief financial officer effective April 1, 2026.Lu is managing partner at Plunkett Capital, with prior senior roles in private banking at Goldman Sachs in Asia.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Indaptus Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 03, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260403:nNDL1w5rJD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2750360997.AUD","IE0004086264.USD","BK4504","IE00BSNM7G36.USD","LU2237443465.HKD","LU2237443895.HKD","LU2471134952.CNY","IE00B19Z3B42.SGD","BK4533","LU1894683348.USD","BK4516","LU1868837136.USD","LU0251131958.USD","LU0742534661.SGD","LU2750360641.GBP","LU1791807156.HKD","LU1868837300.USD","IE0034235188.USD","LU0106831901.USD","LU1894683264.USD","LU1668664300.SGD","LU1868836914.USD","BK4127","IE0004091025.USD","LU2237443382.USD","LU2237443549.SGD","LU0345770308.USD","LU2471134879.HKD","LU2471134796.USD","BK4552","IE00BFXG1179.USD","LU0048573561.USD","LU0061475181.USD","LU2237443978.SGD","LU2237443622.USD","BK4550","BK4139","LU2265009873.SGD","LU1868836757.USD","LU0251142724.SGD","LU0096364046.USD","GSX","LU1868836591.USD","BK4585","IE0002270589.USD","IE00B19Z3581.USD","INDP","LU2237438978.USD","LU2471134523.USD","LU0345770993.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624633894","title":"Indaptus Therapeutics files Form 3; Sino Lion Ventures reports beneficial ownership","url":"https://stock-news.laohu8.com/highlight/detail?id=2624633894","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624633894?lang=en_us&edition=fundamental","pubTime":"2026-04-03 07:17","pubTimestamp":1775171848,"startTime":"0","endTime":"0","summary":"Sino Lion Ventures filed a Form 3 disclosing beneficial ownership of 38,895,000 Indaptus Therapeutics common shares.Filing identifies Sino Lion Ventures as a 10% owner of Indaptus.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Indaptus Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 02, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDL9G5BBv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INDP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624633893","title":"Indaptus Therapeutics files Form 3 for CEO Junyi Dai initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2624633893","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624633893?lang=en_us&edition=fundamental","pubTime":"2026-04-03 07:16","pubTimestamp":1775171772,"startTime":"0","endTime":"0","summary":"Indaptus Therapeutics CEO Junyi Dai reported ownership of 11,250,000 common shares in an initial SEC filing dated March 23, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Indaptus Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 02, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDLddcl7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INDP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622984838","title":"Indaptus Therapeutics FY2025 annual report published; net loss widens to $21 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622984838","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622984838?lang=en_us&edition=fundamental","pubTime":"2026-03-27 02:10","pubTimestamp":1774548653,"startTime":"0","endTime":"0","summary":"Indaptus said it is evaluating strategic options for a post-investment transaction involving an investment in or acquisition of an operating business.David Lazar invested USD 6.0 million through purchases of Series AA and Series AAA preferred stock, and the preferred stock is convertible into 111,000,000 shares of common stock.A special stockholder meeting approved increasing authorized common shares to 1,000,000,000 and approved a reverse stock split range to be set by the board.The company ended enrollment in its Decoy20 monotherapy dosing and later discontinued enrollment in the Decoy20 combination study with BeOne’s anti-PD-1 antibody tislelizumab, with no participants remaining.Indaptus reported a warrant repricing that reduced exercise prices on certain warrants to USD 1.75.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDLbWWw6h:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INDP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622013145","title":"Indaptus investors group discloses 96.2% beneficial ownership after preferred conversion","url":"https://stock-news.laohu8.com/highlight/detail?id=2622013145","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622013145?lang=en_us&edition=fundamental","pubTime":"2026-03-25 04:31","pubTimestamp":1774384306,"startTime":"0","endTime":"0","summary":"Indaptus said David Lazar sold rights in 700,000 shares of Series AAA preferred stock and 196,800 shares of Series AA preferred stock to five purchasers for USD 11.2 million.Assuming conversion of the preferred stock, Yun Yao would beneficially own 37.08% of the company’s common shares.Sino Lion Ventures would beneficially own 34.35% on the same basis.The purchasers said they plan to file a joint Schedule 13D and may be deemed a group, while each purchaser reported sole voting and dispositive power over its own shares.After conversion, David Lazar’s ownership would be about 1.82% of the outstanding common stock.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Indaptus Therapeutics Inc. published the original content used to generate thi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL7dzcVN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INDP"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.indaptusrx.com","stockEarnings":[{"period":"1week","weight":0.0316},{"period":"1month","weight":-0.2648},{"period":"3month","weight":-0.2091},{"period":"6month","weight":-0.0369},{"period":"1year","weight":-0.7361},{"period":"ytd","weight":-0.1031}],"compareEarnings":[{"period":"1week","weight":-0.0059},{"period":"1month","weight":0.0078},{"period":"3month","weight":0.035},{"period":"6month","weight":0.0721},{"period":"1year","weight":0.1647},{"period":"ytd","weight":0.0836}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.454545,"avgChangeRate":-0.037296},{"month":2,"riseRate":0.363636,"avgChangeRate":-0.000875},{"month":3,"riseRate":0.454545,"avgChangeRate":-0.06305},{"month":4,"riseRate":0.363636,"avgChangeRate":0.020664},{"month":5,"riseRate":0.363636,"avgChangeRate":-0.084502},{"month":6,"riseRate":0.545455,"avgChangeRate":0.062667},{"month":7,"riseRate":0.363636,"avgChangeRate":-0.073374},{"month":8,"riseRate":0.4,"avgChangeRate":0.036746},{"month":9,"riseRate":0.363636,"avgChangeRate":-0.055501},{"month":10,"riseRate":0.272727,"avgChangeRate":-0.090558},{"month":11,"riseRate":0.272727,"avgChangeRate":-0.057102},{"month":12,"riseRate":0.454545,"avgChangeRate":-0.026598}],"exchange":"NASDAQ","name":"Indaptus Therapeutics, Inc.","nameEN":"Indaptus Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Indaptus Therapeutics, Inc.(INDP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Indaptus Therapeutics, Inc.(INDP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Indaptus Therapeutics, Inc.,INDP,Indaptus Therapeutics, Inc.股票,Indaptus Therapeutics, Inc.股票老虎,Indaptus Therapeutics, Inc.股票老虎国际,Indaptus Therapeutics, Inc.行情,Indaptus Therapeutics, Inc.股票行情,Indaptus Therapeutics, Inc.股价,Indaptus Therapeutics, Inc.股市,Indaptus Therapeutics, Inc.股票价格,Indaptus Therapeutics, Inc.股票交易,Indaptus Therapeutics, Inc.股票购买,Indaptus Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Indaptus Therapeutics, Inc.(INDP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Indaptus Therapeutics, Inc.(INDP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}